[go: up one dir, main page]

NO20052059L - Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta. - Google Patents

Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta.

Info

Publication number
NO20052059L
NO20052059L NO20052059A NO20052059A NO20052059L NO 20052059 L NO20052059 L NO 20052059L NO 20052059 A NO20052059 A NO 20052059A NO 20052059 A NO20052059 A NO 20052059A NO 20052059 L NO20052059 L NO 20052059L
Authority
NO
Norway
Prior art keywords
interferon
therapies
beta
chronic inflammatory
inflammatory demyelinating
Prior art date
Application number
NO20052059A
Other languages
English (en)
Other versions
NO20052059D0 (no
Inventor
Alfred Sandrock
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of NO20052059D0 publication Critical patent/NO20052059D0/no
Publication of NO20052059L publication Critical patent/NO20052059L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer fremgangsmåter for behandling, og farmaka for anvendelse i behandling, av pattedyr som har, eller med risiko for å utvikle, kroniske . demyeliniserende nevropatier, f.eks. CIDP. Fremgangsmåtene involverer administrering av IFN-ß terapeutika.
NO20052059A 2002-09-27 2005-04-27 Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta. NO20052059L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41430702P 2002-09-27 2002-09-27
PCT/US2003/030532 WO2004028472A2 (en) 2002-09-27 2003-09-26 THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β

Publications (2)

Publication Number Publication Date
NO20052059D0 NO20052059D0 (no) 2005-04-27
NO20052059L true NO20052059L (no) 2005-06-27

Family

ID=32043377

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052059A NO20052059L (no) 2002-09-27 2005-04-27 Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta.

Country Status (21)

Country Link
US (2) US20060182715A1 (no)
EP (1) EP1575531B9 (no)
JP (3) JP2006513990A (no)
KR (1) KR20050059195A (no)
CN (2) CN102038938A (no)
AT (1) ATE520412T1 (no)
AU (1) AU2003277006C1 (no)
BR (1) BR0314548A (no)
CA (1) CA2500189A1 (no)
DK (1) DK1575531T3 (no)
EA (1) EA009289B1 (no)
GE (1) GEP20094699B (no)
IS (1) IS7746A (no)
MX (1) MXPA05003243A (no)
NO (1) NO20052059L (no)
NZ (1) NZ565990A (no)
PL (1) PL377612A1 (no)
RS (1) RS20050255A (no)
UA (1) UA86749C2 (no)
WO (1) WO2004028472A2 (no)
ZA (1) ZA200502416B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565990A (en) * 2002-09-27 2009-10-30 Biogen Idec Inc Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-beta
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
CA2667637C (en) 2006-10-31 2021-04-20 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
EP3348275A3 (en) 2009-03-31 2018-10-24 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
SG10201602076QA (en) * 2011-10-01 2016-04-28 Glytech Inc Glycosylated polypeptide and pharmaceutical composition containing same
GB201212878D0 (en) 2012-07-20 2012-09-05 Pike Justin Authentication method and system
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
GB201520741D0 (en) 2015-05-27 2016-01-06 Mypinpad Ltd And Licentia Group Ltd Authentication methods and systems
KR102454376B1 (ko) * 2018-07-04 2022-10-17 서울대학교산학협력단 신경손상의 면역세포치료
GB201916441D0 (en) 2019-11-12 2019-12-25 Mypinpad Ltd Computer-implemented system and method
WO2026010310A1 (ko) * 2024-07-02 2026-01-08 주식회사 카인사이언스 만성 염증성 탈수초 다발신경병증에 대한 펩타이드의 투여요법
KR20260005778A (ko) * 2024-07-02 2026-01-12 주식회사 카인사이언스 탈수초 질환 치료를 위한 펩타이드 및 IVIg의 병용 요법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
DE3712564A1 (de) * 1987-04-14 1988-11-24 Bioferon Biochem Substanz Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
TW403653B (en) * 1995-12-25 2000-09-01 Otsuka Pharma Co Ltd Dry compositions
HK1042098B (zh) * 1998-10-16 2009-10-30 拜奥根Idec马萨诸塞公司 干扰素-β融合蛋白及用途
TR200101086T2 (tr) * 1998-10-16 2001-08-21 Biogen, Inc. Interferon beta-1A'nın polimer birleşikleri ve kullanımları.
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
CA2363779A1 (en) * 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
AU2002212107A1 (en) * 2000-11-02 2002-05-15 Maxygen Aps New multimeric interferon beta polypeptides
BR0207576A (pt) * 2001-02-27 2004-04-27 Maxygen Aps Variante glicosilada de um polipeptìdeo de interferon beta precursor (ifnb), processos de aumentar a glicosilação in vivo de uma molécula de ifnb precursora, de produzir uma molécula de ifnb glicosilada, para preparar uma variante conjugada e de tratar um mamìfero com esclerose múltiplam composição farmacêutica, molécula de ifnb variante, sequência de nucleotìdeo, vetor de expressão, célula hospedeira de glicosilação conjugado, e, uso de um conjugado
US20030091544A1 (en) * 2001-03-13 2003-05-15 Vical Incorporated Interferon-Beta polynucleotide therapy for autoimmune and inflammatory diseases
NZ565990A (en) * 2002-09-27 2009-10-30 Biogen Idec Inc Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-beta

Also Published As

Publication number Publication date
AU2003277006B2 (en) 2009-09-10
CN1802170A (zh) 2006-07-12
US20060182715A1 (en) 2006-08-17
BR0314548A (pt) 2005-08-09
EP1575531A4 (en) 2008-01-23
ATE520412T1 (de) 2011-09-15
CA2500189A1 (en) 2004-04-08
JP2006513990A (ja) 2006-04-27
NZ565990A (en) 2009-10-30
EP1575531B1 (en) 2011-08-17
IS7746A (is) 2005-03-15
NO20052059D0 (no) 2005-04-27
EP1575531B9 (en) 2012-02-22
CN102038938A (zh) 2011-05-04
KR20050059195A (ko) 2005-06-17
MXPA05003243A (es) 2005-09-12
US20120058083A1 (en) 2012-03-08
AU2003277006C1 (en) 2010-04-01
EA009289B1 (ru) 2007-12-28
ZA200502416B (en) 2005-10-20
EA200500545A3 (ru) 2007-04-27
WO2004028472A2 (en) 2004-04-08
EP1575531A2 (en) 2005-09-21
EA200500545A2 (ru) 2005-08-25
RS20050255A (sr) 2007-08-03
PL377612A1 (pl) 2006-02-06
AU2003277006A1 (en) 2004-04-19
JP2011132248A (ja) 2011-07-07
DK1575531T3 (da) 2011-11-21
GEP20094699B (en) 2009-06-10
WO2004028472A3 (en) 2006-01-19
UA86749C2 (en) 2009-05-25
JP2007039463A (ja) 2007-02-15

Similar Documents

Publication Publication Date Title
WO2004006756A3 (en) THERAPIES FOR RENAL FAILURE USING INTERFERON-β
CA2514473A1 (en) Fused bicyclic nitrogen-containing heterocycles
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
ATE304017T1 (de) Oxazolylpyrazol-derivate als kinase-inhibitoren
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
NO20052059D0 (no) Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta.
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
NO20015991L (no) Bicykliske polyaminosyre-metallkomplekser, fremgangsmåter for fremstilling av disse og deres anvendelse ved medisinsk avbildning
NO20050497L (no) Anvendelse av CETP inhibitorer og eventuelt HMG COA reduserbare inhibitorer og/eller antihypertensiva
DK2201840T3 (da) Hæmmere af Brutons tyrosinkinase
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
NO20070073L (no) Pyrazolderivater, preparater inneholdende disse og metoder for anvendelse derav
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
MXPA04006572A (es) Terapia de combinacion antivirica.
EA200500764A1 (ru) Фармацевтические композиции и лекарственные формы для трансбуккальной и сублингвальной доставки тизанидина и способы введения тизанидина сублингвально или трансбуккально
NO20034561L (no) Anvendelse av kationiske dekstranderivater for beskyttelse av dosebegrensende organer
WO2007120156A3 (en) Animal models of long qt syndrome and uses thereof
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
MY140194A (en) Novel fusidic acid derivatives
CY1105117T1 (el) Θepαπειες για τη χρονια νεφρικη ανεπαρκεια χρησιμοποιωντας ανταγωνιστες των ενσωματινων
ATE544453T1 (de) Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen
DK1708693T3 (da) Farmaceutiske sammensætninger indeholdende platinkomplekser med sekundære xanthater og terapeutiske anvendelser deraf
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.
TW200510447A (en) Novel fusidic acid derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application